MAPT and Alzheimer disease: In this regard, several blood-based biomarkers are evaluated, in which we can highlight (a) The Alz-tau biomarker: validated by four clinical trials, this novel blood-based biomarker allows screening of pre-clinical populations at risk of developing AD.